NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

Celgene needs to find new growth drivers beyond 2020, as its multiple myeloma blockbuster Revlimid is expected to see its sales growth slow in the coming years, even though its place as a backbone ...

Multiple myeloma (MM), which is caused by the transformation ... diagnosed with MM in combination with melphalan (Alkeran; Celgene) and prednisone. This combination, also known as VMP, produced ...

offered a new oral drug option to the group of people suffering from multiple myeloma. Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted ...

But after a seemingly random finger fracture, his doctor tested him for elevated protein levels in his blood and told him he had a form of cancer called multiple myeloma. It was sort of an out-of-body ...

Myeloma develops due to the accumulation of multiple pathological genetic events ... KD Boyd has been involved in Celgene speaker bureaus. C Pawlyn has received conference travel support from ...

Revlimid, the big-selling multiple myeloma drug acquired in Bristol’s buyout of Celgene, will face a new slate of generics in March and then a full generic market in 2026, Boerner said.

the future of myeloma therapy will involve genotyping of individual patient tumors, and designing therapy based on the results. Therapy will become bespoke, targeting the multiple deregulated ...